Sumitomo Pharma Co (STU:DPM) E10: €0.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:DPM Sumitomo Pharma Co Ltd STU:DPM
71 GF Score
Price €6.46
GF Value €4.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co E10?

Sumitomo Pharma Co STU:DPM -5.07% 71 E10 is €0.06 as of Mar. 2026. GuruFocus rates STU:DPM with a GF Score™ of 71/100 and a GF Value™ of €4.66 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Sumitomo Pharma Co's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.011. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.06 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was -47.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Sumitomo Pharma Co was 12.80% per year. The lowest was -47.00% per year. And the median was 6.90% per year.

As of today (2026-07-30), Sumitomo Pharma Co's current stock price is €6.459. Sumitomo Pharma Co's E10 for the quarter that ended in Mar. 2026 was €0.06. Sumitomo Pharma Co's Shiller PE Ratio of today is 107.65.

During the past 13 years, the highest Shiller PE Ratio of Sumitomo Pharma Co was 251.47. The lowest was 7.49. And the median was 24.74.


Sumitomo Pharma Co  (STU:DPM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sumitomo Pharma Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=6.459/0.06
=107.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Sumitomo Pharma Co was 251.47. The lowest was 7.49. And the median was 24.74.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Sumitomo Pharma Co E10 Related Terms


Sumitomo Pharma Co E10 Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co E10 Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.50 -0.06 -0.05 0.06

Sumitomo Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.04 0.07 0.06 0.06

STU:DPM vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Shiller PE Ratio falls into.


STU:DPM
71GF Score
Sumitomo Pharma Co Ltd STU:DPM
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sumitomo Pharma Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.011/112.7000*112.7000
=-0.011

Current CPI (Mar. 2026) = 112.7000.

Sumitomo Pharma Co Quarterly Data

per share eps CPI Adj_EPS
201606 0.178 98.100 0.204
201609 0.056 98.000 0.064
201612 0.384 98.400 0.440
201703 0.036 98.100 0.041
201706 0.497 98.500 0.569
201709 0.395 98.800 0.451
201712 -0.027 99.400 -0.031
201803 0.184 99.200 0.209
201806 0.298 99.200 0.339
201809 0.243 99.900 0.274
201812 0.239 99.700 0.270
201903 0.174 99.700 0.197
201906 0.138 99.800 0.156
201909 0.502 100.100 0.565
201912 0.283 100.500 0.317
202003 -0.068 100.300 -0.076
202006 0.379 99.900 0.428
202009 0.385 99.900 0.434
202012 0.657 99.300 0.746
202103 -0.273 99.900 -0.308
202106 0.091 99.500 0.103
202109 0.615 100.100 0.692
202112 0.194 100.100 0.218
202203 0.194 101.100 0.216
202206 0.553 101.800 0.612
202209 -0.681 103.100 -0.744
202212 -0.198 104.100 -0.214
202303 -0.985 104.400 -1.063
202306 -0.639 105.200 -0.685
202309 -0.461 106.200 -0.489
202312 -0.801 106.800 -0.845
202403 -3.049 107.200 -3.205
202406 0.236 108.200 0.246
202409 -0.764 108.900 -0.791
202412 0.835 110.700 0.850
202503 0.038 111.100 0.039
202506 0.169 111.700 0.171
202509 1.271 112.000 1.279
202512 0.122 113.000 0.122
202603 -0.011 112.700 -0.011

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.06 mean?
Sumitomo Pharma Co (STU:DPM) has a E10 of €0.06 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's E10 too high?
Sumitomo Pharma Co's current E10 is €0.06. Overall, Sumitomo Pharma Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's E10 compare to ZTS?
Sumitomo Pharma Co's E10 of €0.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current E10 is €0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (STU:DPM) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.66, compared to a current price of €6.46 — trading 38.6% above its estimated fair value. The current E10 is €0.06. Sumitomo Pharma Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Sumitomo Pharma Co (STU:DPM), the current E10 is €0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (STU:DPM) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of €6.46 is trading 38.6% above its estimated GF Value™ of €4.66. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for STU:DPM:

  • E10: €0.06
  • GF Value™: €4.66 vs. price of €6.46 (38.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the STU:DPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
71GF Score

Get the complete analysis for STU:DPM

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.46
Price
€4.66
GF Value